SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4024Perfect example: siliconinvestor.com (ARIA)—FDA approves Roche’s Alecensa (aletktom-12/11/2015
4023Sorry my bad. I don't know what I was thinking.testad-12/11/2015
4022wait a minute - you actually read and digest posts from tktom?tktomizwked-12/11/2015
4021testad, from you post, it looks like you don't realize that Ariad was createtktom-12/11/2015
4020Since 1991? You are saying that because you did not sell when the stock was up testad-12/11/2015
4019Looks like zero chance of a buy out now. This is a small company and the value ttktom-12/11/2015
4018Bullish cross in MACD and Stochastic oscillator. Technical 76% chance up at foxcsfnsie-12/9/2015
4017ASH posters available for download at Ariad Nordics... ariadnordics.eujaybe112/9/2015
4016It's academic since IMHO there will be a buyout within 60 days.Denner could civic08801-12/8/2015
4015In justification of the phase III and dose-range finding trials earlier in the ymulanoon2007-12/8/2015
4014Thanks again Jaybe for all that you contribute. If you were on the Scientific Adcivic08801-12/8/2015
4013For OPTIC 2L trial, if prior trial results hold... Nilotinib (400mg BID) shouldjaybe-12/8/2015
4012too short to show safety, and so will have little impact on actual sales even iftktom-12/7/2015
4011And, finally Biomaven final conclusion on the new Ariad trial, which is stunningtktom-12/7/2015
4010 DewDiligence[graphic] Monday, 12/07/15 03:14:26 PM Re: biomaven0 post# 198033 tktom-12/7/2015
4009I tend to agree with Biomaven, the new phase 3 trail is a complete waste of monetktom-12/7/2015
4008Dew with Pona approved as announced today to go into Phase III for Second line ycivic08801-12/7/2015
4007Here's the update on the pona label changes... Renal artery stenosis has bejaybe-12/6/2015
4006No, but likely changes consistent with 48-month data being presented Monday at Ajaybe-12/4/2015
4005Jaybe, do you by any chance know Ariad's modification requests for sectionjesspro-12/4/2015
4004Ariad recently submitted a request to modify sections 5.1 Vascular Occlusion andDonShimoda-12/4/2015
4003So you think NVS is sitting on their BUTT...? No—NVS is busy promoting Tasigna. DewDiligence_on_SI-12/4/2015
4002So you think NVS is sitting on their BUTT.. What do you think they will do? Tellcivic08801-12/4/2015
4001BTW In Europe Actavis' Gleevec is already approved. Roll-out starts after JuTwoPack-12/4/2015
4000The 2/1/16 launch date for generic Gleevec is not exactly news—it’s been known sDewDiligence_on_SI-12/4/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News